Jones P - Search Results

1

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P; TRISTAN Study Group. Vestbo J, et al. Among authors: jones p. Respir Med. 2004 Nov;98(11):1045-50. doi: 10.1016/j.rmed.2004.03.017. Respir Med. 2004. PMID: 15526804 Free article. Clinical Trial.

2

Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD.

Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Meecham Jones DJ, et al. Among authors: jones pw. Am J Respir Crit Care Med. 1995 Aug;152(2):538-44. doi: 10.1164/ajrccm.152.2.7633704. Am J Respir Crit Care Med. 1995. PMID: 7633704 Clinical Trial.

3

Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia?

Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Okubadejo AA, et al. Among authors: jones pw. Eur Respir J. 1996 Nov;9(11):2335-9. doi: 10.1183/09031936.96.09112335. Eur Respir J. 1996. PMID: 8947081 Free article.

4

Quality of life changes in COPD patients treated with salmeterol.

Jones PW, Bosh TK. Jones PW, et al. Am J Respir Crit Care Med. 1997 Apr;155(4):1283-9. doi: 10.1164/ajrccm.155.4.9105068. Am J Respir Crit Care Med. 1997. PMID: 9105068 Clinical Trial.

5

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Burge PS, et al. Among authors: jones pw. BMJ. 2000 May 13;320(7245):1297-303. doi: 10.1136/bmj.320.7245.1297. BMJ. 2000. PMID: 10807619 Free PMC article. Clinical Trial.

6

Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL).

Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Garrod R, et al. Among authors: jones pw. Respir Med. 2000 Jun;94(6):589-96. doi: 10.1053/rmed.2000.0786. Respir Med. 2000. PMID: 10921765 Free article.

7

Health status deterioration in patients with chronic obstructive pulmonary disease.

Spencer S, Calverley PM, Sherwood Burge P, Jones PW; ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Spencer S, et al. Among authors: jones pw. Am J Respir Crit Care Med. 2001 Jan;163(1):122-8. doi: 10.1164/ajrccm.163.1.2005009. Am J Respir Crit Care Med. 2001. PMID: 11208636 Clinical Trial.

8

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

Jones PW. Jones PW. Eur Respir J. 2002 Mar;19(3):398-404. doi: 10.1183/09031936.02.00063702. Eur Respir J. 2002. PMID: 11936514 Free article. Review.

9

Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation.

Jones PW, Wilson K, Sondhi S. Jones PW, et al. Respir Med. 2003 Jan;97(1):20-6. doi: 10.1053/rmed.2002.1425. Respir Med. 2003. PMID: 12556006 Free article. Clinical Trial.

10

Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations.

Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Jones PW, et al. Eur Respir J. 2003 Jan;21(1):68-73. doi: 10.1183/09031936.03.00013303. Eur Respir J. 2003. PMID: 12570111 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,779 results

Search Page

Filters